FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – USA – 05/2025”.
The Monitor is a month-to-month printed overview of enterprise capital developments within the US Healthcare & Life Sciences sector.
As of the top of Could 2025 we recognized the next present VC developments in america:
- Complete Healthcare & Life Sciences funding reached EUR 15,796m (-9% vs. 2024)
- Biotech/Pharma acquired 40% of the overall funding quantity (EUR 6,357m) with oncology being the main indication (27%)
- In Could Neuralink secured the highest transaction quantity with EUR 576m, adopted by Pathos with EUR 327m and Lumicell with EUR 176m
- Illumina (United States) is probably the most lively investor (by deal quantity in 2025), adopted by Regeneron Prescription drugs (United States) and Bain Capital Life Sciences (United States)
To entry the complete report, please click on right here.
By Mathias Klozenbücher und Johannes Hyperlink